New Research In
Physical Sciences
Social Sciences
Featured Portals
Articles by Topic
Biological Sciences
Featured Portals
Articles by Topic
- Agricultural Sciences
- Anthropology
- Applied Biological Sciences
- Biochemistry
- Biophysics and Computational Biology
- Cell Biology
- Developmental Biology
- Ecology
- Environmental Sciences
- Evolution
- Genetics
- Immunology and Inflammation
- Medical Sciences
- Microbiology
- Neuroscience
- Pharmacology
- Physiology
- Plant Biology
- Population Biology
- Psychological and Cognitive Sciences
- Sustainability Science
- Systems Biology
Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity
Edited by Robert Langer, Massachusetts Institute of Technology, Cambridge, MA, and approved January 20, 2011 (received for review October 30, 2010)

Abstract
Chemotherapy-induced broad toxicities are the leading cause of the drug-induced mortality in cancer patients. Antiangiogenic drugs (ADs) in combination with chemotherapy are widely used as front-line therapy for the treatment of various human cancers. However, the beneficial mechanisms underlying combination therapy are poorly understood. Here we show that, in several murine tumor models, administration of sunitinib markedly reduced chemotherapy-induced bone marrow toxicity. Intriguingly, in a sequential treatment regimen, delivery of ADs followed by chemotherapy demonstrated superior survival benefits compared with simultaneous administration of two drugs. In murine tumor models, we show that VEGF increased chemotoxicity by synergistically suppressing bone marrow hematopoiesis with cytostatic drugs. These findings shed light on molecular mechanisms by which ADs in combination with chemotherapy produce survival benefits in cancer patients and provide conceptual information guiding future designs of clinical trials, current practice, and optimization of ADs for the treatment of cancer.
Footnotes
- 1To whom correspondence should be addressed. E-mail: Yihai.Cao{at}ki.se.
Author contributions: Y.C. designed research; D.Z., E.-M.E.H., S.L., F.C., and Y.Z. performed research; B.S. and Y.C. contributed new reagents/analytic tools; D.Z., E.-M.E.H., S.L., F.C., Y.Z., and Y.C. analyzed data; and D.Z. and Y.C. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1016220108/-/DCSupplemental.
Citation Manager Formats
More Articles of This Classification
Biological Sciences
Medical Sciences
Related Content
- No related articles found.
Cited by...
- Novel concept of the smart NIR-light-controlled drug release of black phosphorus nanostructure for cancer therapy
- Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
- Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
- Forty-Year Journey of Angiogenesis Translational Research
- Chemotherapy Enhances Metastasis Formation via VEGFR-1-Expressing Endothelial Cells
- DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo